Wedbush raises Viridian Therapeutic stock price target to $43

Wedbush raised its price target on Viridian Therapeutics to $43 from $32 while keeping an Outperform rating, with the stock trading at $18.80 and analyst targets ranging from $20 to $50. The firm said Lumvoa is priced at $450,000 per course for a 75kg patient, modeled first revenue in Q4 2026 at $34 million versus $27 million consensus, and expects limited payer pushback. The FDA approval of Lumvoa for thyroid eye disease is a major commercial milestone that supports a transition from development-stage biotech to revenue-generating company.

Analysis

VRDN is moving from binary development optionality to a slower but more durable commercial monetization story, and that transition tends to compress volatility only after the market has first overestimated near-term penetration. The key takeaway is not the approval itself; it is that pricing appears anchored near incumbent economics, which reduces the odds of a destructive access fight and supports a multi-year franchise rather than a one-cycle launch spike. That makes the stock less about peak sales hype and more about whether management can convert a large addressable pool into a manageable cadence of treated patients without leakage to competing infusion centers or wait-and-see payers.

The second-order winner may be the broader ophthalmology supply chain: specialty distribution, infusion capacity, and reimbursement services should see incremental demand as the company works through payer onboarding. Conversely, competing thyroid eye disease players face a tougher hurdle if the market concludes that the category can support premium pricing without immediate payer backlash. The bigger competitive risk is not another drug so much as delayed adoption from physician inertia and site-of-care friction, which could push revenue recognition out by quarters even if demand is real.

The stock’s current setup still looks more like a long-duration execution call than a clean one-quarter catalyst trade. The main tail risk is that launch math gets de-rated twice: first by slower payer approvals, then by a smaller treated population than the market is underwriting, which would matter more than price per course. On the other hand, a cash-rich balance sheet means downside is less about solvency and more about multiple compression if early scripts and reimbursement milestones disappoint over the next 2-3 quarters.

Key Decisions for Investors

• Go long VRDN on pullbacks toward the high-teens/low-20s with a 6-12 month horizon; thesis is that cash-backed launch optionality and pricing discipline can re-rate the stock before meaningful revenue, with upside toward the mid-30s if payer friction remains contained.
• Buy VRDN Jan-2027 calls or call spreads to express the delayed-commercialization thesis; the timing mismatch between approval and revenue should make long-dated optionality cheaper than common if the market overfocuses on near-term launch noise.
• Avoid chasing after analyst-target revisions; instead, wait for the first reimbursement and shipment data points, then add on any post-launch de-rating if management shows real prescription conversion.
• Pair trade: long VRDN / short a basket of slower-growth commercial-stage biotech names with weaker balance sheets, as VRDN’s pro forma cash runway reduces financing overhang and should support a premium once launch milestones are visible.
• Use a stop/trim discipline on any long if payer commentary or initial launch metrics indicate that adoption is slipping by more than one quarter versus current expectations; the downside is mostly multiple compression, not balance-sheet distress.